Skip to main content

Table 1 Baseline characteristics based on the status of the primary and secondary endpoints

From: Widely targeted quantitative lipidomics and prognostic model reveal plasma lipid predictors for nasopharyngeal carcinoma

Value N (%) or mean ± SD

Distant metastasis

Progression

Death

Control ( n  = 140)

Case ( n  = 39)

P value a

Control ( n  = 125)

Case ( n  = 54)

P value a

Control ( n  = 162)

Case ( n  = 17)

P value a

Age (yr)

45.2 ± 12.5

47.3 ± 10.6

0.313

45.0 ± 12.8

47.1 ± 10.2

0.249

45.6 ± 12.2

45.9 ± 11.9

0.923

Sex

  

0.106

  

0.028

  

0.566

 Female

42 (30.0)

6 (15.4)

 

40 (32.0)

8 (14.8)

 

45 (27.8)

3 (17.6)

 

 Male

98 (70.0)

33 (84.6)

 

85 (68.0)

46 (85.2)

 

117 (72.2)

14 (82.4)

 

Tumor stage

  

0.027

  

0.002

  

0.071

 T1

8 (5.7)

0 (0)

 

8 (6.4)

0 (0)

 

8 (4.9)

0 (0)

 

 T2

13 (9.3)

2 (5.1)

 

12 (9.6)

3 (5.6)

 

14 (8.6)

1 (5.8)

 

 T3

94 (67.1)

22 (56.4)

 

86 (68.8)

30 (55.6)

 

108 (66.7)

8 (47.1)

 

 T4

25 (17.9)

15 (38.5)

 

19 (15.2)

21 (38.8)

 

32 (19.8)

8 (47.1)

 

Node stage

  

0.007

  

0.001

  

0.671

 N0

18 (12.9)

0 (0)

 

17 (13.6)

1 (1.9)

 

17 (10.5)

1 (5.9)

 

 N1

65 (46.4)

12 (30.8)

 

61 (48.8)

16 (29.6)

 

71 (43.8)

6 (35.3)

 

 N2

34 (24.3)

15 (38.5)

 

29 (23.2)

20 (37.0)

 

44 (27.2)

5 (29.4)

 

 N3

23 (16.4)

12 (30.7)

 

18 (14.4)

17 (31.5)

 

30 (18.5)

5 (29.4)

 

Clinical stage

  

0.002

  

 < 0.001

  

0.025

 III

97 (69.3)

16 (41.0)

 

92 (73.6)

21 (38.9)

 

107 (66.0)

6 (35.3)

 

 IV

43 (30.7)

23 (59.0)

 

33 (26.4)

33 (61.1)

 

55 (34.0)

11 (64.7)

 

BMI (kg/m2)

21.4 ± 1.5

21.9 ± 1.2

0.064

21.4 ± 1.5

21.7 ± 1.3

0.237

21.5 ± 1.5

21.5 ± 1.3

0.924

CHO (mmol/L)

4.9 ± 1.0

4.8 ± 0.8

0.626

4.9 ± 1.0

4.9 ± 0.9

0.575

4.9 ± 0.9

4.9 ± 1.3

0.952

TG (mmol/L)

1.3 ± 0.8

1.2 ± 0.6

0.840

1.2 ± 0.8

1.3 ± 0.6

0.530

1.3 ± 0.7

1.2 ± 0.6

0.625

HDL (mmol/L)

1.3 ± 0.3

1.4 ± 0.3

0.540

1.3 ± 0.3

1.3 ± 0.3

0.895

1.3 ± 0.3

1.4 ± 0.4

0.677

LDL (mmol/L)

3.0 ± 0.9

3.0 ± 0.8

0.588

3.0 ± 0.8

3.1 ± 0.9

0.475

3.0 ± 0.8

3.2 ± 1.4

0.682

WBC (109/L)

7.1 ± 2.0

6.8 ± 1.6

0.424

7.0 ± 1.9

7.1 ± 2.0

0.769

7.0 ± 1.9

6.7 ± 2.4

0.633

Neutrophil (109/L)

4.6 ± 1.7

4.0 ± 1.1

0.018

4.5 ± 1.6

4.4 ± 1.7

0.629

4.5 ± 1.6

4.0 ± 2.1

0.373

Lymphocyte (109/L)

1.8 ± 0.6

2.1 ± 0.7

0.016

1.8 ± 0.6

2.0 ± 0.6

0.056

1.8 ± 0.6

2.0 ± 0.7

0.423

CRP (mg/L)

4.0 ± 7.1

3.7 ± 6.2

0.810

3.8 ± 6.5

4.3 ± 8.0

0.672

3.6 ± 6.1

7.0 ± 12.2

0.281

LDH (U/L)

180.2 ± 47.2

198.8 ± 78.8

0.168

178.8 ± 43.3

196.9 ± 76.7

0.108

183.5 ± 55.3

191.7 ± 62.7

0.608

EBV DNA (copies/ml)

  

0.064

  

0.193

  

0.244

  < 1000

58 (41.4)

14 (35.9)

 

54 (43.2)

18 (33.3)

 

67 (41.4)

5 (29.4)

 

 1000–9999

47 (33.6)

9 (23.1)

 

41 (32.8)

15 (27.8)

 

52 (32.1)

4 (23.5)

 

 10,000–99,999

29 (20.7)

10 (25.6)

 

24 (19.2)

15 (27.8)

 

32 (19.8)

7 (41.2)

 

  ≥ 100,000

6 (4.3)

6 (15.4)

 

6 (4.8)

6 (11.1)

 

11 (6.7)

1 (5.9)

 

Treatment

  

0.703

  

0.488

  

0.013

 CCRT

54 (38.6)

17 (43.6)

 

47 (37.6)

24 (44.4)

 

59 (36.4)

12 (70.6)

 

 ICT + CCRT

86 (61.4)

22 (56.4)

 

78 (62.4)

30 (55.6)

 

103 (63.6)

5 (29.4)

 

 Targeted therapyb

24 (17.1)

3 (7.7)

0.228

21(16.8)

6 (11.1)

0.454

26(16.0)

1 (5.9)

0.476

  1. BMI Body mass index, CHO Cholesterol, TG Triglyceride, HDL High-density lipoprotein cholesterol, LDL Low-density lipoprotein cholesterol, WBC White blood cell, CRP C-reactive protein, LDH Lactate dehydrogenase, EBV Epstein-Barr virus, CCRT Concurrent chemoradiotherapy, ICT Induction chemotherapy
  2. a P values were calculated by the Chi-square test for categorical variables and the Student's T test for continuous variables
  3. bTargeted therapy was defined as treatment with Cetuximab or Nimotuzumab
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X